Impax Labs To Market Pristiq To Neurologists, Implementing Earlier Deal With Wyeth
This article was originally published in The Pink Sheet Daily
Executive Summary
Co-promotion deal will assist Impax in ramping up its commercial team ahead of the launch of its own branded specialty drugs.
You may also be interested in...
Who Stays, Who Goes? Tricky Guessing On Wyeth/Pfizer’s Keeper Deals
"Buyer beware" is more often "seller beware" in the case of takeovers such as Pfizer's proposed mega-grab of Wyeth
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.